Paul E Freeman
Mr. Freiman joined NovaBay’s Board in 2002 and has held various positions during his 17 year tenure at the Company, including Lead Independent Director, Chairman of the Compensation Committee, and since March 2019, Chairman of the Board. Paul E. Freiman currently serves as Chairman of Penwest Pharmaceutical Co., and serves on the boards of Calypte Biomedical Corporation, NeoPharm, Inc., Otsuka America Pharmaceuticals, Inc., and SciGen Ltd. Mr. Freiman was most recently the President and CEO of Neurobiological Technologies Inc. Prior to this role, he held the position of Chairman and CEO of Syntex Corporation, which was sold to The Roche Group for $5.3 billion during his tenure.
Mr. Freiman holds a B.S. degree in pharmacy from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.
Ms. Sit joined NovaBay’s Board in April 2020. Ms. Sit currently acts as an independent business consultant to various public and private companies. Most recently she served as the Vice President of NA Digital Commerce Capabilities, Business Operations and Service and the Vice President of Global Digital Marketing of Nike, Inc. from 2018 to 2019. Prior to such position, Ms. Sit served as the Vice President of Global Digital of Revlon and Elizabeth Arden, Inc. from 2015 to 2017 and the Executive Director of Strategy and Planning, Online of The Estée Lauder Companies, Inc. Ms. Sit brings business experience including digital transformation experience supplemented by management consulting, brand management and advertising. Ms. Sit has built front-end consumer experiences across ecommerce, omnichannel, mobile, media, social, apps and innovation as well as integrated back-end operations.
Ms. Sit received an MBA from Columbia Business School and a B.A. in Economics from Harvard University.
Sean Zheng joined NovaBay’s Board in January 2022. He is the Chief Executive Officer of Q3 Medical Devices (Shanghai) Co. Ltd. Prior to joining Q3 Medical, Mr. Sean Zheng held several Chief Executive positions, including MD of Boill Fund Management (HK) Co., Ltd. and MD and CEO of Sprott- Zijin Mining Fund, a JV fund between Zijin Mining Group and Sprott Asset Management LP. Mr. Sean Zheng has more than 27 years’ experience in mergers and acquisitions, fund management, and import/export business. Mr. Sean Zheng has been a CFA chartered holder since 2006 and graduated from Renmin University of China in 1992.
He holds a B.S degree in Commodity Science. He received his MBA from the University of New South Wales in 2002, and he earned a master’s degree of EMBA from China Europe International Business School (CEIBS) in 2010.
Yenyou (Jeff) Zheng, Ph.D.
Yenyou (Jeff) Zheng, Ph.D. was appointed to NovaBay’s Board of Directors as an independent Board member in September 2019. Dr. Zheng’s experience includes providing innovative financial solutions and consulting services for initial public offering underwriting and investment banking as well as corporate financing solutions with a particular focus on Chinese companies listed overseas. Dr. Zheng previously was a financial advisor for various Canadian public companies including: P & P Ventures Inc. (TSX-V: PPV.H) where he served as president and a director; Damon Capital Corp (TSX-V: DAM.H) where he served as Chief Financial Officer and a director; and Cantronic Systems Inc. (TSX-V: CTS) where he served as a director and chair of the audit committee. Dr. Zheng received a Ph.D in physics from Flinders University of South Australia.
Chief Product Officer
Dr. Audrey Kunin co-founded DERMAdoctor and has led the company since 1998. DERMAdoctor was acquired by NovaBay Pharmaceuticals in 2021 and Dr. Kunin now serves as NovaBay’s Chief Product Officer. Dr. Kunin graduated from Ohio State University in December 1980 and received her M.D. at the Medical College of Ohio in June 1985. She received her postgraduate training in Dermatology at the Medical College of Virginia after serving as Chief Resident in July 1989. She is a fellow of the American Academy of Dermatology and formerly served as an Assistant Clinical Instructor of Dermatology at the University of Kansas School of Medicine.
Ms. Garlikov joined NovaBay’s Board in January 2022. In addition to serving on NovaBay’s Board of Directors, Ms. Garlikov also serves as the Vice President of Marketing of GRAIL, LLC, a biotechnology and pharmaceutical company. She has served in this position since November 2020. Ms. Garlikov has over 25 years of experience in marketing, which includes serving as the Chief Marketing Officer at New Age and Shaklee, as well as senior marketing positions at Rodan & Fields, Obagi Medical and Nuvesse Skin Therapies. Julie is a classically trained CPG marketer who gained her consumer experience at Procter & Gamble, Johnson & Johnson and PepsiCo. She has deep expertise in both health and beauty and eyecare products, as well as in DTC advertising and digital demand generation.
Ms. Garlikov has a Bachelors degree from the University of California, Berkley and a Masters degree in Business Administration from Columbia University.
Justin M. Hall Esq.
Chief Executive Officer
Mr. Hall was appointed to the Board in 2020. He joined NovaBay in February 2013 and currently serves as Company’s Chief Executive Officer & General Counsel. As the chief executive officer and chief legal counsel, Mr. Hall oversees all company operations, including sales, manufacturing, and business development. Prior to joining NovaBay, Mr. Hall worked as the Corporate Counsel of Accuray Incorporated, a radiation oncology company, which he joined in October 2006, where provided substantive legal advice on a broad range of complex legal matters. Mr. Hall’s prior experience also includes serving as a FINRA licensed investment advisor at Sagemark Consulting from 2000 to 2006, and a stock broker at First Security Van Kasper from 1998 to 2001.
Mr. Hall received a B.A. in Business Administration and Management from the University of California, San Diego, and a J.D. from the University of San Diego School of Law.
Mijia (Bob) Wu
Since June 2008, Mr. Wu has been the Managing Director of China Kington, an affiliated entity of China Kington Investment Co. Ltd., which acted as the sole placement agent for a $6.86 million private placement of NovaBay common stock and warrants to purchase common stock in May 2015. Concurrently, he has served as the Managing Director of Shanghai Ceton Investment Management Co. Ltd. Since October 2013, he has also been the Non-Executive Director of China Pioneer Pharmaceutical Holdings Ltd. (“Pioneer”). Previously, he served as Director at UBS AG, Hong Kong Branch, in 2007 and Vice President of BNP Paribas Hong Kong from 2005 to 2006. He was also the Assistant Vice President at ABN AMRO Bank (China) Co., Ltd. from 2002 to 2005. All told, Mr. Wu brings over 10 years of experience in finance and investment to the Board.
He holds a Master in Business Administration from Manchester Business School, University of Manchester and an Executive Master in Business Administration from Cheung Kong Graduate School of Business.
An employee may also submit any concerns or complaints anonymously through our confidential, third-party reporting system, by calling the anonymous telephone hotline at 1-833-778-1552 or by using the confidential web submission system at https://novabaypharma.ethicspoint.com